8-K: Cyclo Therapeutics Secures $3 Million in Convertible Debt from Rafael Holdings Amidst Merger Plans

Cyclo Therapeutics has entered into a third amended agreement with Rafael Holdings, securing a $3 million convertible promissory note, while a merger between the two companies is pending.

Summary

• Cyclo Therapeutics has obtained a $3 million convertible promissory note from Rafael Holdings.
• This agreement is the third amendment to previous note purchase agreements between the two companies.
• The note matures on December 21, 2024, and carries an interest rate of 5% per annum, payable at maturity.
• The principal amount of the note can be converted into Cyclo Therapeutics' common stock at Rafael's option, or automatically upon a qualified financing event.
• The proceeds from the note will be used for working capital and general corporate purposes.
• Rafael Holdings currently holds approximately 31.4% of Cyclo Therapeutics' common stock.
• A merger agreement between Cyclo Therapeutics and a subsidiary of Rafael Holdings is in place, pending shareholder approval and other conditions.

Sentiment

Score: 6

Explanation: The document indicates a necessary funding event for the company, but also highlights the risks associated with debt and potential dilution. The pending merger adds a layer of uncertainty, resulting in a neutral to slightly positive sentiment.

Positives

• Cyclo Therapeutics has secured additional funding of $3 million to support working capital and general corporate purposes.
• The convertible note structure provides flexibility for both Cyclo Therapeutics and Rafael Holdings.
• The existing relationship with Rafael Holdings, a major shareholder, facilitates the funding process.
• The merger agreement, if completed, could provide long-term strategic benefits for Cyclo Therapeutics.

Negatives

• The company is taking on additional debt, which could increase financial risk.
• The convertible nature of the note could lead to dilution of existing shareholders if converted.
• The merger is subject to shareholder approval and other conditions, creating uncertainty.
• Failure to pay the principal or interest on the note, or any of the previous notes, could trigger an event of default and acceleration of the debt.

Risks

• The company's ability to repay the note or secure a qualified financing is uncertain.
• The merger may not be completed, which could impact the company's future plans.
• The conversion of the note could dilute existing shareholders.
• Failure to meet the terms of the note could lead to an event of default and acceleration of the debt.

Future Outlook

The company intends to use the proceeds of the note for working capital and general corporate purposes, and the merger with Rafael Holdings is pending, subject to shareholder approval and other conditions.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

This announcement reflects a trend of smaller biotech companies seeking funding through convertible debt, often from strategic investors, while also pursuing mergers or acquisitions to consolidate resources and expertise.

Comparison to Industry Standards

• The use of convertible notes is a common financing method for companies in the biotechnology sector, particularly those in the development stage.
• The 5% interest rate is relatively standard for this type of financing, although it can vary based on the company's risk profile and market conditions.
• The conversion terms, which are tied to a qualified financing or sale transaction, are also typical in these agreements.
• The merger agreement with Rafael Holdings is similar to other strategic acquisitions in the biotech industry, where larger companies acquire smaller ones to gain access to their technology or pipeline.

Related Party Transactions

• The convertible promissory note was issued to Rafael Holdings, a major shareholder of Cyclo Therapeutics.
• The merger agreement is also with Rafael Holdings, indicating a significant related-party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the convertible note is converted into common stock.
• Employees may be affected by the merger, depending on the integration plans.
• Creditors may be impacted by the increased debt load of the company.
• Customers and suppliers may experience changes depending on the outcome of the merger.

Next Steps

• The company will use the funds for working capital and general corporate purposes.
• The company will seek shareholder approval for the proposed merger with Rafael Holdings.
• The company will monitor the conditions for conversion of the note, including a potential qualified financing or sale transaction.

Key Dates

Keywords

convertible note, promissory note, Rafael Holdings, merger, financing, working capital, common stock, debt, Cyclo Therapeutics